Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

AIMS: Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials. It is unknown if this relationship holds for total (first and subsequent) events. In the ODYSSEY OUTCOMES trial in patients with recent acute coronary syndrome (ACS), the proprotein convertase subti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Heart J
Main Authors: Szarek, Michael, Bittner, Vera A, Aylward, Philip, Baccara-Dinet, Marie, Bhatt, Deepak L, Diaz, Rafael, Fras, Zlatko, Goodman, Shaun G, Halvorsen, Sigrun, Harrington, Robert A, Jukema, J Wouter, Moriarty, Patrick M, Pordy, Robert, Ray, Kausik K, Sinnaeve, Peter, Tsimikas, Sotirios, Vogel, Robert, White, Harvey D, Zahger, Doron, Zeiher, Andreas M, Steg, Ph Gabriel, Schwartz, Gregory G
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724642/
https://ncbi.nlm.nih.gov/pubmed/33051646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa649
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados